Panagora Asset Management Inc. Has $8.17 Million Holdings in LivaNova PLC (NASDAQ:LIVN)

Panagora Asset Management Inc. lifted its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 183.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 157,899 shares of the company’s stock after purchasing an additional 102,235 shares during the quarter. Panagora Asset Management Inc. owned 0.29% of LivaNova worth $8,170,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in LivaNova by 20.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,176 shares of the company’s stock worth $591,000 after purchasing an additional 1,923 shares during the period. Strs Ohio boosted its position in shares of LivaNova by 560.0% during the 3rd quarter. Strs Ohio now owns 9,900 shares of the company’s stock worth $523,000 after acquiring an additional 8,400 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of LivaNova by 2.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 27,202 shares of the company’s stock worth $1,438,000 after acquiring an additional 544 shares in the last quarter. Principal Financial Group Inc. increased its stake in LivaNova by 2.5% in the third quarter. Principal Financial Group Inc. now owns 220,056 shares of the company’s stock valued at $11,637,000 after acquiring an additional 5,291 shares during the last quarter. Finally, Jackson Creek Investment Advisors LLC acquired a new position in LivaNova during the third quarter valued at approximately $914,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Trading Down 1.5 %

Shares of LIVN stock opened at $61.96 on Friday. LivaNova PLC has a 1-year low of $42.75 and a 1-year high of $64.47. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.17 and a quick ratio of 2.71. The stock has a 50-day moving average of $56.24 and a 200-day moving average of $52.00.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, May 1st. The company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.28. LivaNova had a negative net margin of 2.68% and a positive return on equity of 13.59%. The business had revenue of $294.90 million during the quarter, compared to the consensus estimate of $278.17 million. During the same quarter in the prior year, the firm posted $0.43 EPS. The company’s revenue for the quarter was up 12.0% compared to the same quarter last year. As a group, analysts expect that LivaNova PLC will post 2.59 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Mizuho lifted their price target on LivaNova from $75.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. Barclays boosted their target price on LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a research note on Monday, February 26th. Robert W. Baird raised their price target on shares of LivaNova from $58.00 to $66.00 and gave the company a “neutral” rating in a research note on Thursday, May 2nd. StockNews.com upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a research report on Thursday, April 25th. Finally, Needham & Company LLC restated a “buy” rating and issued a $72.00 target price on shares of LivaNova in a research report on Wednesday, May 1st. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $66.20.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.